SOLUTIONS with/in/sight: Cells in the City

Wednesday, November 29, 2017
6:00 p.m. - 8:30 p.m.

They may not have won seven Emmys and eight Golden Globes, yet projects from the Koch Institute Frontier Research Program have hit the big time! The Koch Institute for Integrative Cancer Research hosted an evening of presentations and conversation about two daring cancer research projects turned start-ups that are breaking new ground as they enter the marketplace and move into the clinic. SQZ Biotechnologies is disrupting both cell membranes and biopharma with its cell-squeezing technology for cell therapies, including promising new-to-immunotherapy approaches. Lumicell illuminates cancer at the cellular level, for real-time action during surgery and forward-thinking action in industry. Lead scientists and their corporate partners told the audience about their journeys from bench to biotech, and how grassroots funding from the Koch Institute’s signature Frontier Research Program helped propel these high-risk ideas into high-reward technology.

Featuring presentations by:

Armon Sharei, PhD
Founder & Chief Executive Officer, SQZ Biotechnologies
Former postdoc, Langer Laboratory, Koch Institute at MIT

in conversation with:

Amy Schulman, J.D.
Executive Chair, SQZ Biotechnologies

and:

W. David Lee
President & Chief Scientific Officer, Lumicell

Linda Griffith, PhD
Scientific Advisor, Lumicell
MIT Professor of Biological Engineering and Mechanical Engineering
Member, Koch Institute for Integrative Cancer Research at MIT

Moungi Bawendi, PhD
Scientific Advisor, Lumicell
Lester Wolfe Professor in Chemistry, MIT

View photos on Facebook.